Compare VSTD & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSTD | PPBT |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.5M |
| IPO Year | 2022 | N/A |
| Metric | VSTD | PPBT |
|---|---|---|
| Price | $0.23 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 659.1K | ★ 731.3K |
| Earning Date | 03-27-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,902,861.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.39 | N/A |
| 52 Week Low | $0.20 | $0.53 |
| 52 Week High | $5.63 | $5.20 |
| Indicator | VSTD | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.65 |
| Support Level | N/A | $0.67 |
| Resistance Level | N/A | $0.87 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 17.54 |
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.